“The oral administration of cannabis extracts significantly reduces muscle stiffness in patients with Multiple Sclerosis (MS), according to clinical trial data published in the Journal of Neurology, Neurosurgery and Psychiatry.
Investigators at the University of Plymouth, Clinical Neurology Research Group, in the United Kingdom assessed the use of cannabinoids versus placebo in 279 subjects with MS over a twelve-week period.Cannabis extracts in the study contained standardized doses of THC and Cannabidiol (CBD), a non-psychoactive constituent in cannabis, in a soft gelatin capsule.
Investigators reported that oral cannabis extracts were “superior” over placebo in the treatment of MS-associated muscle stiffness and pain.”
Investigators concluded, “Our results provide evidence that the non-cannabimimetic constituent of marijuana, cannabidiol, exerts clinically relevant antipsychotic effects that are associated with marked tolerability and safety, when compared with current medications. … The results … potentially represent a completely new mechanism in the treatment of schizophrenia.”
A review of CBD’s safety profile in humans, published online in 2011 in the scientific journal Current Drug Safety, concluded that the cannabinoid is non-toxic, safe, and well tolerated in humans, even in high doses.